BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study

结合 医学 药品 抗体-药物偶联物 打开标签 临床研究阶段 抗体 双特异性抗体 肿瘤科 药理学 癌症研究 内科学 单克隆抗体 临床试验 免疫学 数学 数学分析
作者
Yuxiang Ma,Yan Huang,Yuanyuan Zhao,Shen Zhao,Jinhui Xue,Yunpeng Yang,Wen‐Feng Fang,Ye Guo,Yaqian Han,Kunyu Yang,Yongsheng Li,Jun Yang,Zhenming Fu,Gang Chen,Likun Chen,Ningning Zhou,Ting Zhou,Yaxiong Zhang,Huaqiang Zhou,Qianwen Liu
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:25 (7): 901-911 被引量:184
标识
DOI:10.1016/s1470-2045(24)00159-1
摘要

Background Antibody–drug conjugates have promising clinical activity in the treatment of solid tumours. BL-B01D1 is a first-in-class EGFR–HER3 bispecific antibody–drug conjugate. We aimed to assess the safety and preliminary antitumour activity of BL-B01D1 in patients with locally advanced or metastatic solid tumours. Methods This first-in-human, open-label, multicentre, dose-escalation and dose-expansion phase 1 trial was conducted in seven hospitals in China, enrolling patients aged 18–75 years (dose escalation; phase 1a) or older than 18 years (dose expansion; phase 1b), with a life expectancy of at least 3 months, an Eastern Cooperative Oncology Group performance status of 0–1, and histologically or cytologically confirmed locally advanced or metastatic solid tumours that had progressed on current standard treatment. In the phase 1a i3+3 design, patients received intravenous BL-B01D1 at three different schedules: 0·27 mg/kg, 1·5 mg/kg, and 3·0 mg/kg weekly; 2·5 mg/kg, 3·0 mg/kg, and 3·5 mg/kg on days 1 and 8 of each cycle every 3 weeks; or 5·0 mg/kg and 6·0 mg/kg on day 1 of each cycle every 3 weeks. The primary objectives of phase 1a were to identify the safety, maximum tolerated dose, and dose-limiting toxicity. In phase 1b, patients were treated in two schedules: 2·5 and 3·0 mg/kg on days 1 and 8 every 3 weeks, or 4·5, 5·0, and 6·0 mg/kg on day 1 every 3 weeks. The primary objectives of phase 1b were to assess the safety and recommended phase 2 dose of BL-B01D1, and objective response rate was a key secondary endpoint. Safety was analysed in all patients with safety records who received at least one dose of BL-B01D1. Antitumour activity was assessed in the activity analysis set which included all patients who received at least one dose of BL-B01D1 every 3 weeks. This trial is registered with China Drug Trials, CTR20212923, and ClinicalTrials.gov, NCT05194982, and recruitment is ongoing. Findings Between Dec 8, 2021, and March 13, 2023, 195 patients (133 [65%] men and 62 [32%] women; 25 in phase 1a and 170 in phase 1b) were consecutively enrolled, including 113 with non-small-cell lung cancer, 42 with nasopharyngeal carcinomas, 13 with small-cell lung cancer, 25 with head and neck squamous cell carcinoma, one with thymic squamous cell carcinoma, and one with submandibular lymphoepithelioma-like carcinoma. In phase 1a, four dose-limiting toxicities were observed (two at 3·0 mg/kg weekly and two at 3·5 mg/kg on days 1 and 8 every 3 weeks; all were febrile neutropenia), thus the maximum tolerated dose was reached at 3·0 mg/kg on days 1 and 8 every 3 weeks and 6·0 mg/kg on day 1 every 3 weeks. Grade 3 or worse treatment-related adverse events occurred in 139 (71%) of 195 patients; the most common of which were neutropenia (91 [47%]), anaemia (76 [39%]), leukopenia (76 [39%]), and thrombocytopenia (63 [32%]). 52 (27%) patients had a dose reduction and five (3%) patients discontinued treatment due to treatment-related adverse events. One patient was reported as having interstitial lung disease. Treatment-related deaths occurred in three (2%) patients (one due to pneumonia, one due to septic shock, and one due to myelosuppression). In 174 patients evaluated for activity, median follow-up was 6·9 months (IQR 4·5–8·9) and 60 (34%; 95% CI 27–42) patients had an objective response. Interpretation Our results suggest that BL-B01D1 has preliminary antitumour activity in extensively and heavily treated advanced solid tumours with an acceptable safety profile. Based on the safety and antitumour activity data from both phase 1a and 1b, 2·5 mg/kg on days 1 and 8 every 3 weeks was selected as the recommended phase 2 dose in Chinese patients. Funding Sichuan Baili Pharmaceutical. Translation For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Zzzzzzz发布了新的文献求助10
1秒前
1秒前
1秒前
还想长高完成签到 ,获得积分10
1秒前
太阳雨完成签到,获得积分10
2秒前
英子完成签到 ,获得积分10
3秒前
hihi完成签到,获得积分10
3秒前
huhuiya发布了新的文献求助10
3秒前
3秒前
领导范儿的应助被369ninja采纳,获得10
3秒前
乖乖羊完成签到,获得积分10
3秒前
3秒前
一个工人完成签到,获得积分10
4秒前
李子发布了新的文献求助10
4秒前
卡卡滴滴完成签到,获得积分20
5秒前
ZZL完成签到,获得积分10
5秒前
小白完成签到,获得积分10
5秒前
啦啦啦啦啦完成签到 ,获得积分10
6秒前
Zzzzzzz完成签到,获得积分10
7秒前
zbs发布了新的文献求助10
7秒前
fhn716发布了新的文献求助10
7秒前
betterme完成签到,获得积分10
8秒前
Owen的应助被为什么我不行采纳,获得10
8秒前
LCD完成签到,获得积分10
9秒前
Vanli完成签到,获得积分10
9秒前
朴实紫菜完成签到 ,获得积分10
9秒前
奋青发布了新的文献求助10
9秒前
吉不二完成签到,获得积分10
9秒前
小月月发布了新的文献求助10
10秒前
Zz完成签到,获得积分10
10秒前
平淡的凌寒完成签到,获得积分10
10秒前
宋江他大表哥完成签到,获得积分10
10秒前
天天向上的应助被pcs采纳,获得10
10秒前
Wang完成签到,获得积分10
10秒前
木木完成签到,获得积分10
10秒前
孤高曼巴完成签到,获得积分10
10秒前
优雅的项链完成签到,获得积分10
11秒前
lili完成签到,获得积分10
11秒前
xiaoyaczl完成签到,获得积分10
12秒前
害羞菲鹰完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039